Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by Acadian Asset Management LLC

Acadian Asset Management LLC lessened its holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 24.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 602,314 shares of the company’s stock after selling 200,067 shares during the quarter. Acadian Asset Management LLC’s holdings in Y-mAbs Therapeutics were worth $9,792,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. acquired a new position in Y-mAbs Therapeutics in the 4th quarter worth approximately $34,000. Tower Research Capital LLC TRC increased its holdings in Y-mAbs Therapeutics by 345.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,686 shares of the company’s stock worth $46,000 after buying an additional 5,185 shares during the period. Bailard Inc. acquired a new position in Y-mAbs Therapeutics in the 4th quarter worth approximately $115,000. SG Americas Securities LLC increased its holdings in Y-mAbs Therapeutics by 17.5% in the 4th quarter. SG Americas Securities LLC now owns 21,559 shares of the company’s stock worth $147,000 after buying an additional 3,210 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Y-mAbs Therapeutics by 4.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,090 shares of the company’s stock worth $178,000 after buying an additional 1,089 shares during the period. Institutional investors and hedge funds own 70.85% of the company’s stock.

Y-mAbs Therapeutics Stock Down 0.9 %

Shares of NASDAQ YMAB traded down $0.11 during midday trading on Friday, reaching $11.59. 177,387 shares of the stock were exchanged, compared to its average volume of 294,990. The firm has a market cap of $508.57 million, a price-to-earnings ratio of -23.65 and a beta of 0.66. Y-mAbs Therapeutics, Inc. has a twelve month low of $4.60 and a twelve month high of $20.90. The firm has a 50-day simple moving average of $12.03 and a two-hundred day simple moving average of $13.40.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). Y-mAbs Therapeutics had a negative net margin of 25.64% and a negative return on equity of 21.40%. The company had revenue of $19.93 million during the quarter, compared to analyst estimates of $22.06 million. Research analysts expect that Y-mAbs Therapeutics, Inc. will post -0.52 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Truist Financial assumed coverage on shares of Y-mAbs Therapeutics in a report on Friday, June 28th. They issued a “buy” rating and a $21.00 price target on the stock. HC Wainwright raised their price objective on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, May 13th. Two analysts have rated the stock with a sell rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $17.86.

Insider Activity at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 7,351 shares of Y-mAbs Therapeutics stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $13.00, for a total value of $95,563.00. Following the sale, the insider now owns 232,681 shares of the company’s stock, valued at approximately $3,024,853. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Y-mAbs Therapeutics news, insider Thomas Gad sold 7,351 shares of the firm’s stock in a transaction on Thursday, May 23rd. The stock was sold at an average price of $13.00, for a total value of $95,563.00. Following the transaction, the insider now owns 232,681 shares in the company, valued at approximately $3,024,853. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Bo Kruse sold 31,371 shares of the firm’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $12.07, for a total value of $378,647.97. Following the completion of the transaction, the chief financial officer now owns 210,877 shares in the company, valued at approximately $2,545,285.39. The disclosure for this sale can be found here. In the last quarter, insiders have sold 99,444 shares of company stock valued at $1,203,925. 21.50% of the stock is owned by company insiders.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.